简介：AbstractBackground:Taxanes are an essential class of antineoplastic agents used to treat various cancers and are a fundamental cause of hypersensitivity reactions. In addition, other adverse events, such as bone marrow toxicity and peripheral neuropathy, can lead to chemotherapy discontinuation. This study aimed to evaluate the safety of taxanes in the real world.Methods:Taxane-associated adverse events were identified by the Medical Dictionary for Regulatory Activities Preferred Terms and analyzed and compared by mining the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database from January 2004 to December 2019. Reported adverse events, such as hypersensitivity reaction, bone marrow toxicity, and peripheral neuropathy, were analyzed with the following signal detection algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), Bayesian confidence propagation neural network (BCPNN), and logistic regression methods. Adverse outcome events and death outcome rates were compared between different taxane groups using Pearson’s χ2 test, whereas significance was determined at P < 0.05 with a 95% confidence interval (CI).Results:A total of 966 reports of hypersensitivity reactions, 1109 reports of bone marrow toxicity, and 1374 reports of peripheral neuropathy were analyzed. Compared with paclitaxel and docetaxel, bone marrow toxicity following the use of nab-paclitaxel had the highest ROR of 6.45 (95% two-sided CI, 6.05-6.88), PRR of 5.66, (χ2 = 4342.98), information component of 2.50 (95% one-sided CI = 2.34), and empirical Bayes geometric mean of 5.64 (95% one-sided CI = 5.34). Peripheral neuropathy following the use of nab-paclitaxel showed a higher ROR of 12.78 (95% two-sided CI, 11.55-14.14), PRR of 12.16 (χ2 = 4060.88), information component of 3.59 (95% one-sided CI = 3.25), and empirical Bayes geometric mean of 12.07 (95% one-sided CI = 11.09).Conclusions:The results showed that bone marrow toxicity and peripheral neuropathy were the major adverse events induced by taxanes. Nab-paclitaxel exhibited the highest potential for taxane-associated adverse events. Further research in the future is warranted to explain taxane-associated adverse effects in real-world circumstances.

简介：AbstractBackground:The platelet to lymphocyte ratio (PLR) has recently emerged as a potential inflammatory biomarker and has been shown to be significantly associated with atherosclerotic coronary artery disease (CAD). Therefore, we aimed to explore the association of PLR with in-hospital major adverse cardiovascular events (MACEs) and the severity of CAD assessed by the Gensini score (GS) in patients with acute myocardial infarction (AMI) undergoing coronary angiography.Methods:A total of 502 patients with AMI consecutively treated at the Affiliated Hospital of Qingdao University (Qingdao, China) and underwent coronary angiography from August 2017 to December 2018 were recruited in this study. The demographic, clinical, angiographic characteristics, and laboratory parameters were collected. According to the presence of in-hospital MACEs, the included patients were divided into the MACE group (n = 81) and the non-MACE group (n = 421). Further, according to tertiles of the GS, the patients were classified into three groups: the low GS group (GS ≤32 points, n = 173), medium GS group (32 points < GS ≤ 60 points, n = 169), and high GS group (60 points < GS ≤ 180 points, n = 160). The main statistical methods included Chisquared test, non-parametric Mann-Whitney U test, Kruskal-Wallis H test, logistic regression, and receiver operating characteristic curves.Results:The PLR in the MACE group was significantly higher than that in the non-MACE group (179.43 [132.84, 239.74] vs. 116.11 [87.98, 145.45], Z = -8.109, P < 0.001). Further, there were significant differences in PLR among the tertiles of GS (110.05[84.57, 139.06] vs. 119.78 [98.44, 157.98] vs. 140.00 [102.27, 191.83], H= 19.524, P < 0.001). PLR was demonstrated to be an independent risk factor of in-hospital MACEs (odds ratio [OR]: 1.012, 95% confidential interval [CI]: 1.006-1.018, P < 0.001) and severe CAD assessed by the GS (OR: 1.004, 95% CI: 1.002-1.009, P= 0.042). The cutoff value of PLR for predicting the development of in-hospital MACEs was 151.28 with a sensitivity of 66.7% and a specificity of 78.1% (area under the curve [AUC]: 0.786, 95% CI: 0.730-0.842, P < 0.001), and a PLR of 139.31 was also identified to be an effective cutoff point for detecting a high GS (<60 points) with a sensitivity of 49.4% and a specificity of 69.6% (AUC: 0.611, 95% CI: 0.556-0.666, P < 0.001).Conclusions:PLR as a novel inflammatory marker is significantly and independently associated with the occurrence of in-hospital MACEs and the severity of CAD assessed by the GS in patients with AMI. As an easily available and inexpensive inflammatory indicator, PLR could be widely used as an efficient inflammatory biomarker for identifying high-risk patients and for individualizing targeted therapy to improve the prognosis of AMI.

简介：七月雅思考试日历,英孚教育最新事件,新托业考试登陆中国,S．H．E全新“玩乐”专辑《PLAY》在京召开发布会,法国LEPHIL时尚羽绒服2007年秋冬流行趋势发布.

简介：英孚教育最新事件；九月雅思考试日历；沪江6岁生日到，沪友纷纷献贺礼；柏林——越来越多的中国游客向往的城市；INTHEMOODFORLOVE——斯贝瑞[享受]2周年庆典.

简介：BackgroundItiswellknownthattherewasasignificantlinkbetweenpreproceduralbloodglucoselevelsandshort-termandlong-termadverseoutcomesinpatientsundergoingelectivePCI.However,theroleofpre-proceduralbloodglucoselevelsasapredictorofadverseeventsinCKDpatientswhounderwentPCIoutofestablisheddiabeteshasyettobeidentified.MethodsInourstudy,weconductedaprospectivestudyof331acutecoronarysyndrome(ACS)patientswithCKDwhounderwentPCIoutofestablisheddiabetes.Patientsweredividedintotwogroupsbasedonpre-proceduralglucoselevels(hypoglycemia<7.0mmol/L;hyperglycemia≥7.0mmol/L).Allpatientswerefollowedupprospectivelyformajoradversecardiovascularevents(MACEs)andmortalityfor6months.ResultsInourcohort,hyperglycemiapatientsreportedahigherincidenceofin-hospitalmortalitythanhypoglycemiapatients(7.5%vs.0%,P<0.001).Hyperglycemiapatientsreportedasignificantlyhigherrateof6-monthMACEs(10%vs.2.4%,P=0.007),allcausemortality(7.5%vs.1.6%,P=0.015),andcardiovascularmortality(6.2%vs1.6%,P=0.041)comparedwithhypoglycemiapatientswithpre-proceduralglucoselevels<7.0mmol/L.Multivariateanalysisdisclosedthatapre-proceduralglucoselevel≥7.0mmol/LwasasignificantindependentpredictorofMACEs(OR=2.53,95%CI1.68-17.15,P=0.004),allcausemortality(OR=4.6,95%CI1.10-18.84,P=0.036),andcardiovascularmortality(OR=6.2,95%CI1.53-24.94,P=0.011)at6monthsinpatientsafterPCI.ConclusionThestudysuggestedthatpre-proceduralglucoselevelsareassociatedwithshort-termcardiovascularoutcomeCKDpatientswhounderwentPCIwithoutestablisheddiabetesinthesettingofACS.

简介：无

简介：

简介：这篇论文描述有效数据结构，也就是索引的P树，块P树，和索引块P树(或IP树，BP树，和IBP树，分别地为短)为在一个通用离散事件模拟系统维持未来事件，并且在事件地平线原则下面学习他们的事件集合算法的表演。为比较原因，一些著名事件集合算法被选择了并且学习，也就是说theDynamic堆和P树算法。到进给算法并且与另外的选择算法允许比较的建议事件的表演的获得卓见，他们以一个试验性的方法在许多条件下面被测试。为Holdoperation的实行需要的时间为估计算法的平均时间复杂性作为这项措施被花。BP树算法和IBP树算法与所有尺寸和他们的表演的事件集合表现很好的Theexperimental结果表演几乎独立于随机的分布。

简介：ChineseSocietyofRareEarthsDirectorGeneral:Prof.Tel:861062182748Fax:861062173501TreibacherIndustrieAGPresident:Mr.ReinhardIroManagingDirectorResponsibleForREBusiness:Mr.AlexanderBouvierTel:00434262505570Fax:004342622898AMRTechnologiesInc.Chairman:ArchibaldCox,Jr.Tel:0014163678588Fax:0014163675471RhodiaElectronics&CatalysisVicePresident:ZhuMingyueTel:862154422630Fax:862154422302BaotouRareEarthHi-TechDevelopmentZoneDirector:Prof.SuWenqingTel:864725159784/5128065Fax:864725156391ChinaR...

简介：

简介：~~

简介：

简介：ChineseSocietyofRareEarthsDirectorGeneral:Prof.BiQunTel:861062182748Fax:861062173501TreibacherIndustrieAGPresident:InaHotzerTel:004342625058240Fax:004342625058240AMRTechnologiesIncPresident:PeterV.GundyTel:0014163678588Fax:0014163675471RhodiaElectronics&CatalysisVicePresident:ZhuMingyueTel:862154422630Fax:862154422302BaotouRareEarthHi-TechDevelopmentZone

简介：

简介：ChineseSocietyofRareEarthsDirectorGeneral:Prof.Tel:861062182748Fax:861062173501TreibacherIndustrieAGPresident:Mr.ReinhardIroManagingDirectorResponsibleForREBusiness:Mr.AlexanderBouvierTel:00434262505570Fax:004342622898AMRTechnologiesInc.President:PeterV.GundyTel:0014163678588Fax:0014163675471RhodiaElectronics&CatalysisVicePresident:ZhuMingyueTel:862154422630Fax:862154422302BaotouRareEarthHi-TechDevelopmentZoneDirector:Prof.SuWenq...

简介：ChineseSocietyofRareEarthsDirectorGeneral:Prof.BiQunTel:861062182748Fax:861062173501TreibacherIndustrieAGPresident:Mr.ReinhardIroManagingDirectorResponsibleForREBusiness:Mr.AlexanderBouvierTel:004342625058240Fax:004342625058240AMRTechnologiesInc.President:PeterV.GundyTel:0014163678588Fax:0014163675471RhodiaElectronics&CatalysisVicePresident:ZhuMingyueTel:862154422630Fax:862154422302BaotouRareEarthHi-TechDevelopmentZoneDirector:Prof.SuWenqin...

简介：ChineseSocietyofRareEarthsDirectorGeneral:Prof.BiQunTel:861062182748Fax:861062173501BaotouRareEarthHI-TechDevelopmentZoneDirector:Prof.SuWenqingTel:864725159784/5128065Fax:864725156391ChinaRareEarthHoldingsLimitedPresident:JiangQuanlongTel:865107456666Fax:865107454730

简介：ChineseSocietyofRareEarthsDirectorTel:861062182748Fax:861062173501TreibacherIndustrieAGPresident:Mr.ReinhardIroManagingDirectorResponsibleForREBusiness:Mr.AlexanderBouvierTel:00434262505570Fax:004342622898AMRTechnologiesInc.Chairman:ArchibaldCox,Jr.Tel:0014163678588Fax:0014163675471RhodiaElectronics&CatalysisVicePresident:ZhuMingyueTel:862154422630Fax:862154422302BaotouRareEarthHi-TechDevelopmentZoneDirector:Prof.SuWenqingTel:86...

简介：ChineseSoeietyofRareEalthsDireCtorGeneral:Prof.BiQunTel:861062182748臼X:861062173501丁reibacherIndust犷ieAGPresident:M「Reinh己rdIroManagingDirectorResPonsib[e向rREBusiness:M「AlexanderBouvierTel:00434262505570臼x:004342622898AMRTeehnologieslne-President:PeterV.GundyTel:0014163678588臼x:0014163675471肋odiaEle比ronics压Cata皿ysisVicePresident:ZhuMingyueTe】:862154422630自x:86215科22302Baotou肋reEalthHi.T七ehDevelopmentZoneDirector:Prof.SuWenqingTel:864725159784151280...

简介：